Navigating Treatment Options in Low-Risk Myelodysplastic Syndromes

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

Luspatercept Controls Anemia in Transfusion Dependent MDS Population

Stem Cell Transplant Approaches for Patients With Blood Cancers

Health Insurance, Income, and Marital Status Contribute to Blood Cancer Disparities

PD-L1 Expression Confers Worse Myelodysplastic Syndrome

Ruxolitinib Receives Positive NICE Opinion for Polycythemia Vera

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

Luspatercept Controls Anemia in Transfusion Dependent MDS Population

Stem Cell Transplant Approaches for Patients With Blood Cancers

Health Insurance, Income, and Marital Status Contribute to Blood Cancer Disparities

PD-L1 Expression Confers Worse Myelodysplastic Syndrome

Ruxolitinib Receives Positive NICE Opinion for Polycythemia Vera

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

Luspatercept Controls Anemia in Transfusion Dependent MDS Population

Stem Cell Transplant Approaches for Patients With Blood Cancers

Health Insurance, Income, and Marital Status Contribute to Blood Cancer Disparities

PD-L1 Expression Confers Worse Myelodysplastic Syndrome

Ruxolitinib Receives Positive NICE Opinion for Polycythemia Vera

Related Content

Data from a previous MPN LANDMARK survey highlight that many patients with polycythemia vera experience symptoms that lead to reduced quality of life.

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

Data from a previous MPN LANDMARK survey highlight that many patients with polycythemia vera experience symptoms that lead to reduced quality of life.

Luspatercept Controls Anemia in Transfusion Dependent MDS Population

Podcast

The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.

Luspatercept may provide clinical benefit regardless of subgroup and baseline mutation burden in transfusion dependent patients with myelodysplastic syndrome with anemia, according to Guillermo Garcia-Manero, MD.

Stem Cell Transplant Approaches for Patients With Blood Cancers

Luspatercept may provide clinical benefit regardless of subgroup and baseline mutation burden in transfusion dependent patients with myelodysplastic syndrome with anemia, according to Guillermo Garcia-Manero, MD.

Health Insurance, Income, and Marital Status Contribute to Blood Cancer Disparities

Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

Marisol Miranda-Galvis, DDS, MS, PhD, highlights the importance of identifying populations of patients with hematologic cancer who are underserved and using socially targeted solutions.

PD-L1 Expression Confers Worse Myelodysplastic Syndrome

Marisol Miranda-Galvis, DDS, MS, PhD, highlights the importance of identifying populations of patients with hematologic cancer who are underserved and using socially targeted solutions.

Patients with dyserythropoiesis appear to have higher PD-L1 expression than those without in a study population of those with myelodysplastic syndromes.